GlassScriptPhysician profile
Chris Y Wu
NPI 1265829345
$11,163.56
in general payments reported to CMS, 2019-2025
13 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $406 · 2021: $124 · 2022: $206 · 2023: $388 · 2024: $8,760 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,860 · Food and Beverage: $1,838 · Travel and Lodging: $756 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,860.00 |
| Food and Beverage | $1,838.25 |
| Travel and Lodging | $755.55 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,295.21 | 2022-2025 | Vabysmo |
| Alcon Vision LLC | $1,042.30 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $482.65 | 2022-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $289.43 | 2023-2024 | Iluvien, Yutiq |
| Abbvie INC. | $271.26 | 2022-2025 | Ozurdex |
| Eyepoint US, INC. | $269.61 | 2021-2023 | |
| Shire North American Group INC | $124.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $108.18 | 2019 | |
| Ani Pharmaceuticals, INC. | $101.56 | 2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Apellis Pharmaceuticals, INC. | $54.10 | 2023-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $45.56 | 2023-2024 | Xipere |
| Astellas Pharma US INC | $14.17 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.